Skip to main content
icon for 特朗普將宣布誰成為下一任FDA委員?

特朗普將宣布誰成為下一任FDA委員?

icon for 特朗普將宣布誰成為下一任FDA委員?

特朗普將宣布誰成為下一任FDA委員?

Kyle Diamantas 53%

No announcement by December 31 11.6%

Stephen Hahn 4%

Sara Brenner 3.3%

Polymarket
最新

Kyle Diamantas 53%

No announcement by December 31 11.6%

Stephen Hahn 4%

Sara Brenner 3.3%

Polymarket
最新

Kyle Diamantas

$1,525 交易量

53%

Stephen Hahn

$976 交易量

4%

Brett Giroir

$1,510 交易量

3%

Grace Graham

$1,893 交易量

3%

Sara Brenner

$849 交易量

3%

No announcement by December 31

$533 交易量

12%

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump’s recent decision to name Kyle Diamantas acting FDA commissioner following Marty Makary’s May 2026 resignation has positioned Diamantas as the frontrunner in trader assessments for a permanent appointment. Diamantas, who previously led the agency’s Human Foods Program and served as a senior counselor to HHS Secretary Robert F. Kennedy Jr., has advanced administration priorities on food additives and safety standards aligned with the Make America Healthy Again agenda. The administration has stated that a formal search for a confirmed commissioner is underway with Senate confirmation required, which introduces standard procedural timelines and potential delays. Other named candidates, including former commissioner Stephen Hahn and Brett Giroir, register lower probabilities amid limited recent signals of endorsement, while the option of no announcement by year-end reflects ongoing uncertainty over the pace of the selection process.

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.

An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.

Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.

Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.

A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.

If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.

The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
交易量
$7,286
結束日期
2026-12-31
市場開放時間
May 12, 2026, 7:59 PM ET
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump’s recent decision to name Kyle Diamantas acting FDA commissioner following Marty Makary’s May 2026 resignation has positioned Diamantas as the frontrunner in trader assessments for a permanent appointment. Diamantas, who previously led the agency’s Human Foods Program and served as a senior counselor to HHS Secretary Robert F. Kennedy Jr., has advanced administration priorities on food additives and safety standards aligned with the Make America Healthy Again agenda. The administration has stated that a formal search for a confirmed commissioner is underway with Senate confirmation required, which introduces standard procedural timelines and potential delays. Other named candidates, including former commissioner Stephen Hahn and Brett Giroir, register lower probabilities amid limited recent signals of endorsement, while the option of no announcement by year-end reflects ongoing uncertainty over the pace of the selection process.

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.

An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.

Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.

Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.

A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.

If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.

The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
交易量
$7,286
結束日期
2026-12-31
市場開放時間
May 12, 2026, 7:59 PM ET
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.

警惕外部連結哦。

Frequently Asked Questions

"特朗普將宣布誰成為下一任FDA委員?" is a prediction market on Polymarket with 6 possible outcomes where traders buy and sell shares based on what they believe will happen. The current leading outcome is "Kyle Diamantas" at 53%, followed by "No announcement by December 31" at 12%. Prices reflect real-time crowd-sourced probabilities. For example, a share priced at 53¢ implies that the market collectively assigns a 53% chance to that outcome. These odds shift continuously as traders react to new developments and information. Shares in the correct outcome are redeemable for $1 each upon market resolution.

"特朗普將宣布誰成為下一任FDA委員?" is a newly created market on Polymarket, launched on May 13, 2026. As an early market, this is your opportunity to be among the first traders to set the odds and establish the market's initial price signals. You can also bookmark this page to track volume and trading activity as the market gains traction over time.

To trade on "特朗普將宣布誰成為下一任FDA委員?," browse the 6 available outcomes listed on this page. Each outcome displays a current price representing the market's implied probability. To take a position, select the outcome you believe is most likely, choose "Yes" to trade in favor of it or "No" to trade against it, enter your amount, and click "Trade." If your chosen outcome is correct when the market resolves, your "Yes" shares pay out $1 each. If it's incorrect, they pay out $0. You can also sell your shares at any time before resolution if you want to lock in a profit or cut a loss.

The current frontrunner for "特朗普將宣布誰成為下一任FDA委員?" is "Kyle Diamantas" at 53%, meaning the market assigns a 53% chance to that outcome. The next closest outcome is "No announcement by December 31" at 12%. These odds update in real-time as traders buy and sell shares, so they reflect the latest collective view of what's most likely to happen. Check back frequently or bookmark this page to follow how the odds shift as new information emerges.

The resolution rules for "特朗普將宣布誰成為下一任FDA委員?" define exactly what needs to happen for each outcome to be declared a winner — including the official data sources used to determine the result. You can review the complete resolution criteria in the "Rules" section on this page above the comments. We recommend reading the rules carefully before trading, as they specify the precise conditions, edge cases, and sources that govern how this market is settled.